Active Filter(s):
Details:
The agreement provides Tetra with access to novel patented new molecules with CB1 and CB2 agonist or antagonist properties.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Tetra BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 27, 2020